STOCKHOLM, SWEDEN – Vironova AB, a leading Nano-Characterization technology and software company announced the approval of a new patent application. The US Patent Office (USPTO) has granted Vironova a patent for a Thionation reagent (no 13/936423). This patent is expected to be valid until 2032. Corresponding patents have been applied for all major markets. Based … Read more
Finance and Accounting Manager
Konsult från Almarekonmi byrå. Tigare anställd på Vironova AB
Principal Scientist
Ph.D. in Organic Chemistry from the Zelinsky Institute of Organic Chemistry (Russian Acad. Science). M.Sc. in Chemistry from The Moscow State University. Employed at Vironova Medical AB since 2020. Previously at Uppsala Universitet, Novadex AB and Medivir AB.
Marketing Director
Chief of Communication at Vironova AB. He has been in management roles and worked as a management consultant providing consultative advice and services in strategy development with focus towards digital strategy and transformation framework, demand and lead generation management, sales and marketing strategy. Working with C-level and middle management with change initiatives to bridge the gap between strategy and execution. Mats holds a M.Sc. in Financial Economics from Gothenburg University. Previously CMO and Management Consultant at ProSales Institute and ProSales Consulting.
Investor Relations
Text coming soon…
CEO
Ph.D. in Medicine from the Karolinska Institute. M.Sc. in Biotechnology from The Royal Institute of Technology. Employed at Vironova AB and Vironova Medical AB since 2014. Previously CSO at Vironova Medical AB.
Board Member
M.Sc., Stockholm School Economics, MBA University of California, Berkeley
20+ years of experience in board positions, currently board member at Prolight Diagnostics, Newfour, QBNK. Previously CEO at several Swedish companies including AGA Gas, Thermiaverken and Candor.
Suppleant
Ph.D. in Polymer Technology from The Royal Institute of Technology. Previous manager at Akzo Nobel. AB. Board member in Vironova AB.
Board Member
M.Sc., Stockholm School of Economics. Board Member in RISE, N-side, Leuwen Belgium, and Nobelux. Industrial adviser at EQT. 25 years of experience in the pharmaceutical industry, most recently 10 years as President Europe in Astra Zeneca, based in Brussels.
Board Member
Professor in anesthesiology and intensive care since 1999 at the Department of Clinical Science, Intervention and Technology at Karolinska Institute. Commercial pharmaceutical “Adenosine” in the U.S. market through licensing with Astellas Pharma.
Co-founder and Chairman
M.Sc. In Chemistry and B.Sc. in Biology from Uppsala University. Founder and Chairman of the board in Vironova AB and founder of Vironova Medical AB.